𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Calpain-mediated androgen receptor breakdown in apoptotic prostate cancer cells

✍ Scribed by Huanjie Yang; Shalini Murthy; Fazlul H. Sarkar; Shijie Sheng; G. Prem-Veer Reddy; Q. Ping Dou


Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
210 KB
Volume
217
Category
Article
ISSN
0021-9541

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Since androgen receptor (AR) plays an important role in prostate cancer development and progression, androgen‐ablation has been the frontline therapy for treatment of advanced prostate cancer even though it is rarely curative. A curative strategy should involve functional and structural elimination of AR from prostate cancer cells. We have previously reported that apoptosis induced by medicinal proteasome‐inhibitory compound celastrol is associated with a decrease in AR protein levels. However celastrol‐stimulated events contributing to this AR decrease have not been elucidated. Here, we report that a variety of chemotherapeutic agents, including proteasome inhibitors, a topoisomerase inhibitor, DNA‐damaging agents and docetaxel that cause cell death, decrease AR levels in LNCaP prostate cancer cells. This decrease in AR protein levels was not due to the suppression of AR mRNA expression in these cells. We observed that a proteolytic activity residing in cytosol of prostate cancer cells is responsible for AR breakdown and that this proteolytic activity was stimulated upon induction of apoptosis. Interestingly, proteasome inhibitor celastrol‐ and chemotherapeutic drug VP‐16‐stimulated AR breakdown was attenuated by calpain inhibitors calpastatin and N‐acetyl‐L‐leucyl‐L‐leucyl‐L‐methioninal. Furthermore, AR proteolytic activity pulled down by calmodulin‐agarose beads from celastrol‐treated PC‐3 cells showed immunoreactivity to a calpain antibody. Taken together, these results demonstrate calpain involvement in proteasome inhibitor‐induced AR breakdown, and suggest that AR degradation is intrinsic to the induction of apoptosis in prostate cancer cells. J. Cell. Physiol. 217: 569–576, 2008. © 2008 Wiley‐Liss, Inc.


📜 SIMILAR VOLUMES


Differential transactivation by the andr
✍ Snoek, Robert; Bruchovsky, Nicholas; Kasper, Susan; Matusik, Robert J.; Gleave, 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 232 KB 👁 2 views

## BACKGROUND. The purpose of this study was to determine the contribution of different transactivating regions of the androgen receptor (AR) to the induction of androgen-regulated promoters in poorly (PC3 cells) and well-differentiated (LNCaP cells) prostate cancer cell lines. METHODS. PC3 and LN

Gene expression changes following androg
✍ Iris E. Eder; Petra Haag; Mark Basik; Spyro Mousses; Jasmin Bektic; Georg Bartsc 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 355 KB

## Abstract We have shown recently that inhibition of androgen receptor (AR) expression with an antisense AR oligonucleotide (ODN) inhibits LNCaP prostate tumor cells in vitro as well as in vivo. In this study, we investigated gene expression changes that occur after AR signaling blockade, either t

Androgen receptor modifications in prost
✍ Rute B. Marques; Sigrun Erkens-Schulze; Corrina M. de Ridder; Karin G. Hermans; 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 392 KB

## Abstract To study the mechanisms whereby androgen‐dependent tumors relapse in patients undergoing androgen blockade, we developed a novel progression model for prostate cancer. The PC346C cell line, established from a transurethral resection of a primary tumor, expresses wild‐type (wt) androgen

PKC-mediated secretion of death factors
✍ Liqing Xiao; Anatilde Gonzalez-Guerrico; Marcelo G. Kazanietz 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 243 KB

## Abstract Activation of PKCδ in androgen‐dependent LNCaP prostate cancer cells leads to apoptosis via the activation of p38 MAPK and JNK cascades. We have recently shown that treatment of LNCaP cells with phorbol 12‐myristate 13‐acetate (PMA) leads to a PKCδ‐mediated autocrine release of death fa